The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership.
New research published in Blood sheds light on diagnosis, disease characteristics, and prognoses for inherited hematologic malignancies associated with DDX41 germline variants.
ARUP’s latest autonomous intelligent vehicle (AIV) is on a mission to save time and trouble for its coworkers in the lab. As a new teammate, the AIV is a seamless and helpful fit.
The Summer 2022 edition of Magnify, now online, features a look at the challenges of autoimmune neurologic testing, our experts in this area, and recent awards, and catches up with a former fellow.
Eric Duncavage, MD, has a passion for pathology that thrives in the space between technology and the possibilities for its use to improve patient care. His path to a career in technology-driven translational medicine ran through ARUP Laboratories.
As a child growing up on her family’s vegetable farm, Tammy Smith, MD, PhD, spent a lot of time thinking about the rhythm of an ecosystem. “You’ve got precipitation, soil, sun, nutrients, invasive species,” she said. “You’ve got all these things interacting, so how do you ensure they work well…
ARUP medical directors and scientists will share their research and expertise in areas like lab stewardship, biochemical genetics, and neonatal drug testing at AACC’s 2022 annual meeting in Chicago.
Scientist Michael T. Pyne shares ARUP’s challenges and process of developing a next generation sequencing (NGS) test for HIV-1 antiretroviral drug resistance.
ARUP experts are to give six talks and poster presentations at the flagship annual meeting of the American Society for Microbiology (ASM) in Washington, D.C.